CO2022000575A2 - Composiciones sólidas que comprenden un derivado de egf(a) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico - Google Patents
Composiciones sólidas que comprenden un derivado de egf(a) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílicoInfo
- Publication number
- CO2022000575A2 CO2022000575A2 CONC2022/0000575A CO2022000575A CO2022000575A2 CO 2022000575 A2 CO2022000575 A2 CO 2022000575A2 CO 2022000575 A CO2022000575 A CO 2022000575A CO 2022000575 A2 CO2022000575 A2 CO 2022000575A2
- Authority
- CO
- Colombia
- Prior art keywords
- hydroxybenzoyl
- egf
- amino
- caprylic acid
- salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se refiere a composiciones farmacéuticas que comprenden un inhibidor de PCSK9, tal como un péptido de EGF(A), y una sal de ácido N-(8-(2-hidroxibenzoil)amino)caprílico. La invención se refiere además a procesos para la preparación de dichas composiciones, y a su uso en medicina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19190506 | 2019-08-07 | ||
PCT/EP2020/072227 WO2021023855A1 (en) | 2019-08-07 | 2020-08-07 | Solid compositions comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2022000575A2 true CO2022000575A2 (es) | 2022-04-29 |
Family
ID=67551283
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2022/0000575A CO2022000575A2 (es) | 2019-08-07 | 2022-01-24 | Composiciones sólidas que comprenden un derivado de egf(a) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220323544A1 (es) |
EP (1) | EP4009958A1 (es) |
KR (1) | KR20220046565A (es) |
CN (1) | CN114222581A (es) |
AR (1) | AR122299A1 (es) |
AU (1) | AU2020326265A1 (es) |
BR (1) | BR112022000529A2 (es) |
CA (1) | CA3144618A1 (es) |
CO (1) | CO2022000575A2 (es) |
IL (1) | IL289505A (es) |
MX (1) | MX2022000889A (es) |
PE (1) | PE20220486A1 (es) |
TW (1) | TW202120118A (es) |
WO (1) | WO2021023855A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117979958A (zh) * | 2021-07-15 | 2024-05-03 | 诺和诺德股份有限公司 | 包含n-(8-(2-羟基苯甲酰基)氨基)辛酸盐的片剂 |
WO2023012263A1 (en) | 2021-08-04 | 2023-02-09 | Novo Nordisk A/S | Solid oral peptide formulations |
WO2024110614A1 (en) | 2022-11-25 | 2024-05-30 | Novo Nordisk A/S | Oral administration of peptide therapeutics, such as glp-1 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
EP1149066B1 (en) | 1999-02-05 | 2005-11-09 | Emisphere Technologies, Inc. | Method of preparing alkylated salicylamides |
AU2001275231A1 (en) | 2000-06-02 | 2001-12-11 | Emisphere Technologies, Inc. | Method of preparing salicylamides |
US8927015B2 (en) | 2006-04-12 | 2015-01-06 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
US7544833B2 (en) | 2006-09-07 | 2009-06-09 | Hoffmann-La Roche Inc. | Methods for producing N-(8-[2-hydroxybenzoyl]-amino) caprylic acid |
RS56998B1 (sr) | 2010-12-16 | 2018-05-31 | Novo Nordisk As | Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline |
JP2014519848A (ja) | 2011-06-20 | 2014-08-21 | ジェネンテック, インコーポレイテッド | Pcsk9結合ポリペプチドと使用方法 |
CN104203221A (zh) * | 2012-03-22 | 2014-12-10 | 诺和诺德A/S(股份有限公司) | 包含递送剂的组合物及其制备 |
WO2013139694A1 (en) | 2012-03-22 | 2013-09-26 | Novo Nordisk A/S | Compositions of glp-1 peptides and preparation thereof |
ES2916998T3 (es) | 2016-01-13 | 2022-07-06 | Novo Nordisk As | Análogos del EGF(A) con sustituyentes de ácidos grasos |
CN109475593A (zh) * | 2016-06-24 | 2019-03-15 | 豪夫迈·罗氏有限公司 | 用于治疗心血管疾病的组合物和方法 |
US20200165313A1 (en) | 2017-07-19 | 2020-05-28 | Novo Nordisk A/S | Egf(a) analogues, preparation, formulations and uses thereof |
-
2020
- 2020-08-07 CN CN202080055600.1A patent/CN114222581A/zh not_active Withdrawn
- 2020-08-07 TW TW109126752A patent/TW202120118A/zh unknown
- 2020-08-07 WO PCT/EP2020/072227 patent/WO2021023855A1/en unknown
- 2020-08-07 CA CA3144618A patent/CA3144618A1/en not_active Withdrawn
- 2020-08-07 US US17/628,697 patent/US20220323544A1/en not_active Abandoned
- 2020-08-07 MX MX2022000889A patent/MX2022000889A/es unknown
- 2020-08-07 AR ARP200102265A patent/AR122299A1/es unknown
- 2020-08-07 AU AU2020326265A patent/AU2020326265A1/en not_active Withdrawn
- 2020-08-07 BR BR112022000529A patent/BR112022000529A2/pt not_active Application Discontinuation
- 2020-08-07 PE PE2022000111A patent/PE20220486A1/es unknown
- 2020-08-07 KR KR1020227004059A patent/KR20220046565A/ko unknown
- 2020-08-07 EP EP20750288.1A patent/EP4009958A1/en not_active Withdrawn
-
2021
- 2021-12-29 IL IL289505A patent/IL289505A/en unknown
-
2022
- 2022-01-24 CO CONC2022/0000575A patent/CO2022000575A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
AR122299A1 (es) | 2022-08-31 |
MX2022000889A (es) | 2022-02-14 |
IL289505A (en) | 2022-02-01 |
BR112022000529A2 (pt) | 2022-03-03 |
PE20220486A1 (es) | 2022-04-04 |
TW202120118A (zh) | 2021-06-01 |
WO2021023855A1 (en) | 2021-02-11 |
KR20220046565A (ko) | 2022-04-14 |
CN114222581A (zh) | 2022-03-22 |
EP4009958A1 (en) | 2022-06-15 |
CA3144618A1 (en) | 2021-02-11 |
AU2020326265A1 (en) | 2022-02-03 |
US20220323544A1 (en) | 2022-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020009997A2 (es) | Composiciones sólidas que comprenden un agonista de glp-1, una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico y un lubricante | |
CL2020002797A1 (es) | Composiciones sólidas que comprenden un agonista de glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
CO2022005904A2 (es) | Composiciones sólidas que comprenden un inhibidor de pcsk9 y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
CO2022000575A2 (es) | Composiciones sólidas que comprenden un derivado de egf(a) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
CO2022000578A2 (es) | Composiciones sólidas que comprenden un agonista del glp-1, un inhibidor del sglt2 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
CL2017002727A1 (es) | Composiciones de ácido obeticólico y métodos de uso | |
CL2019003324A1 (es) | Sales y formas sólidas de un antibiótico de monobactam. (divisional solicitud 201800745) | |
EA201591751A1 (ru) | Трипептидные эпоксикетонные ингибиторы протеазы | |
DOP2011000264A (es) | Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia | |
CY1126067T1 (el) | Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30) | |
HN2003000044A (es) | Esteres hidroxamato del acido n - (4-fenil sustituido)-antranilico. | |
EA202091318A1 (ru) | Препарат, содержащий аденовирус группы b | |
CO2021014260A2 (es) | Formas sólidas de un inhibidor de glyt1 | |
CO2017008426A2 (es) | Ácido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4- [(5-metiloxazol-2-carbonil)amino]pentanoico | |
ECSP21067816A (es) | Formulaciones farmacéuticas | |
ECSP21060917A (es) | Formulación de anticuerpos terapéuticos | |
UY38067A (es) | Péptidos de la cadena b de la relaxina modificados y su uso terapéutico | |
CL2017003201A1 (es) | Variantes de il-37 | |
CL2023000491A1 (es) | Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020). | |
ES2517741B1 (es) | Composición para reducir y/o prevenir la caída del cabello y/o estimular su crecimiento | |
BR112018070626A2 (pt) | formulação farmacêutica, e, composto ou composição para uso, uso, método ou composição | |
CO2024000581A2 (es) | Comprimido que comprende una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
AR122297A1 (es) | Composiciones sólidas que comprenden un agonista del glp-1, un inhibidor del sglt2 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
CO2024000463A2 (es) | Forma polimórfica a de n-(8-(2- hidroxibenzoil)amino)caprilato de sodio | |
CL2022001035A1 (es) | Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas |